These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
00904-7209 Market Analysis and Financial Projection
Here is an analysis of the market and price projections for the drug with NDC 00904-7209:
Key details:
NDC 00904-7209 is for sevelamer hydrochloride tablets manufactured by Major Pharmaceuticals
Sevelamer hydrochloride is a phosphate binder used to treat high phosphorus levels in patients with chronic kidney disease on dialysis
Market analysis:
The global phosphate binder market was valued at $2.3 billion in 2022 and is projected to reach $3.5 billion by 2030, growing at a CAGR of 5.4% from 2023 to 2030[1].
Key drivers of growth include increasing prevalence of chronic kidney disease and end-stage renal disease requiring dialysis.
Sevelamer is one of the leading phosphate binders, with a significant market share. However, it faces competition from newer agents like sucroferric oxyhydroxide.
Major manufacturers of sevelamer include Genzyme/Sanofi, Aurobindo, and Cipla, in addition to generic manufacturers like Major Pharmaceuticals.
Price projections:
As a generic medication, sevelamer hydrochloride pricing has declined significantly since brand name Renagel lost patent protection.
The average wholesale price (AWP) for sevelamer hydrochloride 800 mg tablets was around $6-7 per tablet in 2022[2].
Prices are expected to remain relatively stable, with potential for modest decreases of 1-3% annually as additional generic competition enters the market.
However, increasing demand may help offset downward pricing pressure to some degree.
Reimbursement rates from Medicare and private insurers will be a key factor influencing pricing. Any significant changes to reimbursement policy could impact market dynamics.
Overall, pricing is projected to decline gradually at 1-3% per year over the next 3-5 years, barring any major regulatory or competitive changes in the phosphate binder market.
In summary, sevelamer hydrochloride remains an important treatment option in a growing market, but as a mature generic product it faces ongoing pricing pressure. Modest price declines are expected in the coming years as the phosphate binder market becomes increasingly competitive.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.